# Sermorelin Dosage in the Research Literature: Doses, Routes, Half-Life

> Sermorelin dosage as documented in studies: 30 mcg/kg/day at bedtime in the pediatric trial, 0.5-1 mg twice daily in aging research, ~10-12 min half-life. Research framing only, cited.

What was administered, to which population, by which route — reported as study parameters, never as a protocol to follow.

## Read this first

This page describes **sermorelin dosage** exactly as it appears in published studies — the amounts researchers gave, to whom, and how. It is not a how-to. Sermorelin here is research-grade material for laboratory work, not a medicine to self-administer, so there are no human dosing instructions on this page — only the study record. Where a number appears, it is paired with the population it was tested in (children, older men, healthy volunteers) and the study that measured it. Doses are written as "studied at X in [population]," never as a recommendation.

## Doses studied in the sermorelin research literature

The dose record spans three distinct research contexts, each with its own amount and route.

**Pediatric growth-deficiency efficacy.** The multicenter pediatric trial used 30 mcg/kg/day subcutaneous at bedtime, which accelerated first-year height velocity from ~4.1 to ~7-8 cm/year [2]. Bedtime timing aligned dosing with the body's nocturnal GH pulse.

**Aging research in older men.** The aging study used 0.5 mg and 1 mg subcutaneous twice daily for 14 days; the high dose reversed age-related GH and IGF-1 declines, with no fasting-glucose change [3].

**Pharmacokinetic and diagnostic work.** In healthy men, intravenous GHRH(1-29) at 0.25-2 mcg/kg released growth hormone, with maximal release around 1-2 mcg/kg [13]; a single intravenous bolus (commonly ~1 mcg/kg) was historically used diagnostically to test pituitary GH reserve.

These figures describe what was administered in controlled studies. They are not converted into, and should not be read as, a personal dose.

### Routes studied

Subcutaneous injection was the primary research route. Intravenous dosing was used for pharmacokinetic and diagnostic studies. An intranasal route was tested historically but achieved only ~3-5% bioavailability [13] — one reason non-injected formulations are viewed skeptically.

## Half-life of sermorelin

The **sermorelin half-life** is brief: roughly ~10-12 minutes in plasma after intravenous administration. GHRH(1-29) is eliminated rapidly, yet a single dose still elevates serum growth hormone for about 3 hours — the downstream GH effect outlasts the peptide's own presence in the blood [13].

That short window is the pharmacologic reason longer-acting analogs were engineered. Stabilizing modifications such as a D-Ala2 substitution and the albumin-binding DAC technology behind CJC-1295 extend the action of a peptide that would otherwise clear in minutes [13], and PEGylation is a further documented half-life-extension strategy for GRF analogs [5]. The contrast is covered in full on [sermorelin vs CJC-1295](/vs-cjc-1295).

## Formulation and stability in the research context

Sermorelin acetate is supplied as a lyophilized (freeze-dried) powder and reconstituted with sterile diluent before use; once reconstituted, it is typically refrigerated. The lyophilized form exists because aqueous peptide solutions degrade — the same fragility that makes a stable salt and cold storage necessary [5]. In the compounding setting, preparations are made under USP sterile-compounding standards.

### Is 3 months of sermorelin enough?

Study durations vary by endpoint: acute GH release appears within hours [3], GH/IGF-1 shifts were measured over 14 days [3], and the pediatric growth endpoint spanned the first year of therapy [2]. The corpus does not define an adult "course length"; the durations described are study timeframes, not protocols to follow.

---

A night research board of the sermorelin literature — slow-wave sleep, the nocturnal growth-hormone pulse, and the GHRH(1-29) findings pinned and cited, with the body-composition data taped where it belongs as tesamorelin and the empty adult-safety clipping left torn open; no clinic behind the board and nothing here dosed, dispensed, or sold.